Type of CBM and cannabinoid profile for each time-point
| CBM information | Baseline [N (%)] | 3-Month [N (%)] |
|---|---|---|
| Treatment was discontinued at 3 month | 0 | 11 (2.2) |
| Type of CBM | ||
| Medical cannabis (plant-derived) | 366 (73.9) | 363 (75) |
| Pharmaceutical cannabinoids (all nabilone) | 2 (0.4) | 6 (1.2) |
| Medical + pharmaceutical | 127 (25.7) | 115 (23.8) |
| Cannabinoid profile | ||
| CBD-dominant | 246 (49.7) | 174 (35.2) |
| THC:CBD balanced | 247 (49.9) | 293 (59.2) |
| THC-dominant | 2 (0.4) | 17 (3.4) |
| Formulation characteristics of medical cannabis | ||
| Ingested oil products | 404 (81.6) | 382 (77.2) |
| Dried flower products | 4 (0.8) | 7 (1.4) |
| Ingested oil and dried flower products | 72 (14.5) | 71 (14.3) |
| Other combinations of formulations (topical, edible, oil, dried) | 15 (3) | 35 (7.1) |
The total sample size for baseline is 495 and 484 for 3-month (11 participants discontinued treatment at 3-month). N (%): the number of people under current conditions (percentage of people under current conditions)